Drug Detail

Drug Name Paclitaxel
Trade Name Taxol
Synonyms 7-Epipaclitaxel
Drug Descriptions

Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).

DrugClasses Antimicrotubule Agent 11 BCL2 Family Inhibitor 6

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Panitumumab + Paclitaxel
Navitoclax + Paclitaxel
Bevacizumab + Capecitabine + Paclitaxel
BAY1161909 + Paclitaxel
Disarib + Paclitaxel
Carboxyamidotriazole Orotate + Paclitaxel
AZD9150 + Durvalumab + Paclitaxel
Enzalutamide + Paclitaxel
Paclitaxel + Lapatinib + Trastuzumab
LCL161 + Paclitaxel
Bevacizumab + Carboplatin + Durvalumab + Paclitaxel
Paclitaxel + Plicamycin
Copanlisib + Paclitaxel
ARQ092 + Paclitaxel
Lenvatinib + Carboplatin + Paclitaxel
Paclitaxel + Carboplatin
Carboplatin + Paclitaxel + Pemetrexed + Veliparib
Nivolumab + Carboplatin + Paclitaxel
Paclitaxel + TS-1
Durvalumab + Oleclumab + Paclitaxel
Nutlin-3 + Paclitaxel
MK-1775 + Paclitaxel
Docetaxel + Paclitaxel + Vinflunine
Bevacizumab + Carboplatin + Paclitaxel
Cediranib + Carboplatin + Paclitaxel
Carboplatin + Paclitaxel + VS-6063
ALRN-6924 + Paclitaxel ALRN-6924 binds to MDM2 and MDM4 (MDMX) and prevents their interaction with p53, resulting in restoration of p53 activity and potentially leading to increased tumor cell death (PMID: 29643228).
MEK162 + Paclitaxel
Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel
LY2109761 + Paclitaxel
Bazedoxifene + Paclitaxel
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
Doxil + Paclitaxel
MRK-003 + Paclitaxel
Paclitaxel + trastuzumab emtansine
Nivolumab + Ipilimumab + Carboplatin + Paclitaxel
Paclitaxel + Ifosfamide
Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel
vorinostat + Paclitaxel
Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel
Neratinib + Paclitaxel + Pertuzumab + Trastuzumab
MLN2480 + Paclitaxel
JQ1 + Paclitaxel
Cisplatin + Paclitaxel + Pembrolizumab
Sapitinib + Paclitaxel
MK2206 + Paclitaxel
Alisertib + Taxol
Orlistat + Paclitaxel
Carboplatin + Paclitaxel + Motesanib
Cyclophosphamide + Epirubicin + Paclitaxel
Paclitaxel + Rebastinib
Cetuximab + Cisplatin + Paclitaxel
SC13 + Paclitaxel
Cemiplimab + Carboplatin + Paclitaxel
Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib
Paclitaxel + Carboplatin + Trastuzumab
Vemurafenib + Carboplatin + Paclitaxel
Ramucirumab + Paclitaxel Cyramza (ramucirumab) in combination with paclitaxel is FDA approved for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (FDA.gov).
INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel
XL147 + Paclitaxel
CFI-402257 + Paclitaxel CFI-402257 selectively inhibits TTK (MPS1), resulting in chromosomal segregation errors, and potentially leading to decreased tumor cell growth (PMID: 28270606, PMID: 29378962).
Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel
Olaparib + Paclitaxel
Panobinostat + Carboplatin + Paclitaxel
LEE011 + Carboplatin + Paclitaxel
Carboplatin + Ipilimumab + Paclitaxel
Afatinib + Paclitaxel
Capivasertib + Paclitaxel
SRT1460 + Paclitaxel
OMP-305B83 + Paclitaxel
Avelumab + Carboplatin + Paclitaxel + Talazoparib
Carboplatin + Cisplatin + Durvalumab + Paclitaxel
NVP-BSK805 + paclitaxel
Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab
Bevacizumab + Paclitaxel
Lurbinectedin + Paclitaxel + Bevacizumab
Selumetinib + Paclitaxel
Dasatinib + Paclitaxel + Carboplatin
INCB001158 + Paclitaxel
Amuvatinib + Paclitaxel + Carboplatin
Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine
Mps-BAY2b + Paclitaxel
Carboplatin + Paclitaxel + Sapanisertib
KX2-391 + Paclitaxel
Afatinib + Carboplatin + Paclitaxel
SRT1720 + Paclitaxel
Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab
Bevacizumab + Emactuzumab + Paclitaxel
Crenolanib + Paclitaxel + Ramucirumab
Paclitaxel + Trastuzumab + TVB-2640
Carboplatin + Paclitaxel + Talazoparib
BKM120 + Carboplatin + Paclitaxel
Motesanib + Paclitaxel
ABT-165 + Paclitaxel
Paclitaxel + TVB-2640
Lurbinectedin + Paclitaxel
Axitinib + Paclitaxel + Carboplatin
Carboplatin + Ipatasertib + Paclitaxel
Gemcitabine + Ibrutinib + Paclitaxel
Imatinib + Carboplatin + Paclitaxel
Olaparib + Paclitaxel + Pembrolizumab
Paclitaxel + Carboplatin + Hydroxychloroquine
Bevacizumab + Cisplatin + Paclitaxel
Mps-BAY1 + Paclitaxel
TAS-119 + Paclitaxel
GSK2256098 + Paclitaxel
Carboplatin + Paclitaxel + PDR001
XL147 + Carboplatin + Paclitaxel
Cobimetinib + Paclitaxel
BGB-A317 + Carboplatin + Paclitaxel
Afuresertib + Carboplatin + Paclitaxel
Carboplatin + Docetaxel + Paclitaxel + Pevonedistat
Paclitaxel + Pembrolizumab
Vistusertib + Paclitaxel
Bevacizumab + Olaparib + Paclitaxel + Pembrolizumab
Ipilimumab + Nivolumab + Paclitaxel
Doxorubicin + Paclitaxel
Cisplatin + Everolimus + Paclitaxel
Pazopanib + Paclitaxel
Mps-BAY2a + Paclitaxel
Bevacizumab + Topotecan + Paclitaxel
Anlotinib + Carboplatin + Paclitaxel
MK-1775 + Carboplatin + Paclitaxel
Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide
Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab
Atezolizumab + Ipatasertib + Paclitaxel
Carboplatin + Paclitaxel + Vorinostat
MEDI5117 + Paclitaxel
Neratinib + Paclitaxel
SPC3042 + Taxol
ABBV-181 + ABT-165 + Paclitaxel ABT-165 is a bispecific antibody that binds to and inhibits signaling of both DLL4 and VEGF, which results in tumor growth inhibition (PMID: 29592882).
Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110
Buparlisib + Paclitaxel
BYL719 + Paclitaxel
Carboplatin + Paclitaxel + Temsirolimus
Paclitaxel + Cetuximab
Carboplatin + Fluorouracil + Paclitaxel + Vandetanib
Carboplatin + M7824 + Paclitaxel
Cirmtuzumab + Paclitaxel
Paclitaxel + Ribociclib
Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide
ACY-1215 + Paclitaxel
Carboplatin + Paclitaxel + Panitumumab
Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab
Iniparib + Paclitaxel
Carboplatin + Paclitaxel + Trametinib
Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab
Paclitaxel + Triciribine
NANT non-small cell lung cancer vaccine
Nintedanib + Carboplatin + Paclitaxel
Paclitaxel Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Belinostat + Carboplatin + Paclitaxel
Paclitaxel + Trastuzumab + MM-111
Ramucirumab + Paclitaxel + Carboplatin
Sorafenib + Carboplatin + Paclitaxel
Crizotinib + Trastuzumab + Paclitaxel
Carboplatin + Cetuximab + Paclitaxel
Carboplatin + Galunisertib + Paclitaxel
Bevacizumab + Paclitaxel + Pembrolizumab
Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab
Ipatasertib + Paclitaxel
Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel
Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide
CCT244747 + Radiotherapy + Paclitaxel
RO4929097 + Paclitaxel
Carboplatin + Ganetespib + Paclitaxel + Radiotherapy
Carboplatin + Paclitaxel + Selinexor
Gedatolisib + Paclitaxel + Carboplatin
Carboplatin + Cisplatin + Epacadostat + Gemzar + Nivolumab + Taxol + Pemetrexed
Paclitaxel + TAK-659 TAK-659 is an inhibitor of spleen tyrosine kinase (SYK), which may lead to B-cell inhibition and antitumor activity (http://meetinglibrary.asco.org/content/134551-144).
Paclitaxel + Taselisib
Paclitaxel + Carboplatin + Metformin
Carboplatin + MLN4924 + Paclitaxel
Carboplatin + Paclitaxel + PTC596
Paclitaxel + Pexidartinib
Vantictumab + Paclitaxel
Everolimus + Paclitaxel
Cetuximab + Paclitaxel + Carboplatin + Erlotinib
Paclitaxel + Ramucirumab + TRK-950
LY411575 + Paclitaxel
Carboplatin + Durvalumab + Paclitaxel
Carboplatin + Neratinib + Paclitaxel
Sorafenib + Cisplatin + Paclitaxel
Carboplatin + Paclitaxel + TSR-042
Cisplatin + Paclitaxel + Bevacizumab + Olaparib
Pazopanib + Carboplatin + Paclitaxel
MEDI3617 + Paclitaxel
Napabucasin + Paclitaxel
Demcizumab + Paclitaxel
Galunisertib + Paclitaxel
Lapatinib + Paclitaxel
AC + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab
Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
Docetaxel + Irinotecan + Paclitaxel
Paclitaxel + TRX-E-002-1
APX005M + Paclitaxel + Carboplatin
Lapatinib + Carboplatin + Paclitaxel
Linifanib + Paclitaxel + Carboplatin
Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab
Ruxolitinib + Paclitaxel
Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed
Atezolizumab + Carboplatin + Paclitaxel
Pertuzumab + Trastuzumab + Paclitaxel
Cisplatin + Paclitaxel
DKN-01 + Paclitaxel
Carboplatin + MEDI3617 + Paclitaxel
Trametinib + Paclitaxel
Durvalumab + Paclitaxel
ACY-241 + Paclitaxel
Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab
AC + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
Carboplatin + Cisplatin + Docetaxel + Paclitaxel
Dinaciclib + Paclitaxel
Ipafricept + Carboplatin + Paclitaxel
ASTX-660 + Paclitaxel
Carboplatin + Paclitaxel + Pembrolizumab
Paclitaxel + Pembrolizumab + Trastuzumab
Paclitaxel + Taladegib
Oregovomab + Carboplatin + Paclitaxel
ONC201 + Paclitaxel
Nivolumab + Paclitaxel + Relatlimab
Onartuzumab + Paclitaxel + Carboplatin
Lapatinib + Carboplatin + Cisplatin + Paclitaxel
Fostamatinib + Paclitaxel
Carboplatin + Enzalutamide + Paclitaxel
EG12014 + Paclitaxel
Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin
Capivasertib + Durvalumab + Paclitaxel
Bevacizumab-awwb + Carboplatin + Paclitaxel
Paclitaxel + Carboplatin + Docetaxel
Doxil + Letrozole + Tamoxifen + Paclitaxel
Everolimus + Paclitaxel + Carboplatin + Cetuximab
Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab
Paclitaxel + Doxorubicin + Cyclophosphamide
Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab
Docetaxel + Paclitaxel
Carboplatin + Erlotinib + Paclitaxel
Paclitaxel + sEphB4-HSA
Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel
Emactuzumab + Paclitaxel
AC + Anastrozole + Paclitaxel + Pertuzumab + Trastuzumab
Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed
Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel Limited information is currently available on EG12014 (Jan, 2019).
Paclitaxel + Sonidegib
MYL-1401O + Paclitaxel
Onartuzumab + Erlotinib + Paclitaxel + Carboplatin
Cyclophosphamide + Paclitaxel
Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab
BMS-906024 + Paclitaxel
Trastuzumab + Paclitaxel
Cetuximab + Cisplatin + Paclitaxel + Radiotherapy
Durvalumab + Paclitaxel + Selumetinib
Paclitaxel + Reparixin
BAY1217389 + Paclitaxel
Paclitaxel + talimogene laherparepvec
Ganetespib + Paclitaxel + Trastuzumab
AC + exemestane + Paclitaxel + Pertuzumab + Trastuzumab
Ridaforolimus + Paclitaxel
Atezolizumab + Paclitaxel
Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, urothelial carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
CCT007093 + Paclitaxel
Lenvatinib + Paclitaxel
Carboplatin + Paclitaxel + Veliparib
Carboplatin + Cisplatin + Paclitaxel + Pemetrexed
Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib
Nivolumab + Paclitaxel
Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab
Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib
AZD6738 + Paclitaxel
Cyclophosphamide + Paclitaxel + Trastuzumab
Paclitaxel + MLN0128 + MLN1117